A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma

H. M. Pinedo, H. T. Mouridsen, R. Somers, A. Santor, Y. H. Mulder, V. Blanwell, A. T. Van Oosterom, R. Sylvester, D. Thomas

Research output: Contribution to journalArticle

Abstract

In advanced measurable soft tissue sarcoma, a randomized study of doxorubicin versus epirubicin was performed, using a dosage of 75 mg/m2 for both. The trial was conducted on a cross-over basis; if the patients progressed on doxorubicin they were crossed over to epirubicin and vice versa. There were 75 evaluable patients in each group, aged 15-18 years, all with a performance status of not less than 50. Detailed figures of the results are given. Comparing the two groups, the complete v. partial remission rates were not statistically significant. The overall response rate for doxorubicin-treated patients was slightly higher than that for those treated with epirubicin. Duration of response was about the same in each group and the survival time for the two groups was equal. Haematological toxicity, nausea and alopecia were greater with doxorubicin than with epirubicin. There were insufficient data to study the cardiotoxicity. It is concluded that doxorubicin remains the anthracycline of first choice for the treatment of soft tissue sarcomas and that in future comparisons of doxorubicin with epirubicin they should be given at haematological equitoxic doses.

Original languageEnglish (US)
Pages (from-to)231-241
Number of pages11
JournalClinical Trials Journal
Volume24
Issue numberSUPPL. 1
StatePublished - 1987
Externally publishedYes

Fingerprint

Epirubicin
Sarcoma
Doxorubicin
Anthracyclines
Alopecia
Nausea
Survival

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pinedo, H. M., Mouridsen, H. T., Somers, R., Santor, A., Mulder, Y. H., Blanwell, V., ... Thomas, D. (1987). A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma. Clinical Trials Journal, 24(SUPPL. 1), 231-241.

A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma. / Pinedo, H. M.; Mouridsen, H. T.; Somers, R.; Santor, A.; Mulder, Y. H.; Blanwell, V.; Van Oosterom, A. T.; Sylvester, R.; Thomas, D.

In: Clinical Trials Journal, Vol. 24, No. SUPPL. 1, 1987, p. 231-241.

Research output: Contribution to journalArticle

Pinedo, HM, Mouridsen, HT, Somers, R, Santor, A, Mulder, YH, Blanwell, V, Van Oosterom, AT, Sylvester, R & Thomas, D 1987, 'A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma', Clinical Trials Journal, vol. 24, no. SUPPL. 1, pp. 231-241.
Pinedo HM, Mouridsen HT, Somers R, Santor A, Mulder YH, Blanwell V et al. A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma. Clinical Trials Journal. 1987;24(SUPPL. 1):231-241.
Pinedo, H. M. ; Mouridsen, H. T. ; Somers, R. ; Santor, A. ; Mulder, Y. H. ; Blanwell, V. ; Van Oosterom, A. T. ; Sylvester, R. ; Thomas, D. / A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma. In: Clinical Trials Journal. 1987 ; Vol. 24, No. SUPPL. 1. pp. 231-241.
@article{b9d0e906db0e406f930d29b053613b34,
title = "A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma",
abstract = "In advanced measurable soft tissue sarcoma, a randomized study of doxorubicin versus epirubicin was performed, using a dosage of 75 mg/m2 for both. The trial was conducted on a cross-over basis; if the patients progressed on doxorubicin they were crossed over to epirubicin and vice versa. There were 75 evaluable patients in each group, aged 15-18 years, all with a performance status of not less than 50. Detailed figures of the results are given. Comparing the two groups, the complete v. partial remission rates were not statistically significant. The overall response rate for doxorubicin-treated patients was slightly higher than that for those treated with epirubicin. Duration of response was about the same in each group and the survival time for the two groups was equal. Haematological toxicity, nausea and alopecia were greater with doxorubicin than with epirubicin. There were insufficient data to study the cardiotoxicity. It is concluded that doxorubicin remains the anthracycline of first choice for the treatment of soft tissue sarcomas and that in future comparisons of doxorubicin with epirubicin they should be given at haematological equitoxic doses.",
author = "Pinedo, {H. M.} and Mouridsen, {H. T.} and R. Somers and A. Santor and Mulder, {Y. H.} and V. Blanwell and {Van Oosterom}, {A. T.} and R. Sylvester and D. Thomas",
year = "1987",
language = "English (US)",
volume = "24",
pages = "231--241",
journal = "Clinical Trials Journal",
issn = "0009-9325",
publisher = "Elsevier BV",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma

AU - Pinedo, H. M.

AU - Mouridsen, H. T.

AU - Somers, R.

AU - Santor, A.

AU - Mulder, Y. H.

AU - Blanwell, V.

AU - Van Oosterom, A. T.

AU - Sylvester, R.

AU - Thomas, D.

PY - 1987

Y1 - 1987

N2 - In advanced measurable soft tissue sarcoma, a randomized study of doxorubicin versus epirubicin was performed, using a dosage of 75 mg/m2 for both. The trial was conducted on a cross-over basis; if the patients progressed on doxorubicin they were crossed over to epirubicin and vice versa. There were 75 evaluable patients in each group, aged 15-18 years, all with a performance status of not less than 50. Detailed figures of the results are given. Comparing the two groups, the complete v. partial remission rates were not statistically significant. The overall response rate for doxorubicin-treated patients was slightly higher than that for those treated with epirubicin. Duration of response was about the same in each group and the survival time for the two groups was equal. Haematological toxicity, nausea and alopecia were greater with doxorubicin than with epirubicin. There were insufficient data to study the cardiotoxicity. It is concluded that doxorubicin remains the anthracycline of first choice for the treatment of soft tissue sarcomas and that in future comparisons of doxorubicin with epirubicin they should be given at haematological equitoxic doses.

AB - In advanced measurable soft tissue sarcoma, a randomized study of doxorubicin versus epirubicin was performed, using a dosage of 75 mg/m2 for both. The trial was conducted on a cross-over basis; if the patients progressed on doxorubicin they were crossed over to epirubicin and vice versa. There were 75 evaluable patients in each group, aged 15-18 years, all with a performance status of not less than 50. Detailed figures of the results are given. Comparing the two groups, the complete v. partial remission rates were not statistically significant. The overall response rate for doxorubicin-treated patients was slightly higher than that for those treated with epirubicin. Duration of response was about the same in each group and the survival time for the two groups was equal. Haematological toxicity, nausea and alopecia were greater with doxorubicin than with epirubicin. There were insufficient data to study the cardiotoxicity. It is concluded that doxorubicin remains the anthracycline of first choice for the treatment of soft tissue sarcomas and that in future comparisons of doxorubicin with epirubicin they should be given at haematological equitoxic doses.

UR - http://www.scopus.com/inward/record.url?scp=0023597485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023597485&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023597485

VL - 24

SP - 231

EP - 241

JO - Clinical Trials Journal

JF - Clinical Trials Journal

SN - 0009-9325

IS - SUPPL. 1

ER -